Fludarabine (NSC 118218)

For research use only. Not for use in humans.

目录号：S1491 别名： FaraA, Fludarabinum 中文名称：氟达拉滨

Fludarabine (NSC 118218) Chemical Structure

CAS No. 21679-14-1

Fludarabine (NSC 118218, FaraA, Fludarabinum)在血管平滑肌细胞中是一种STAT1活化抑制剂，特异性降低STAT1蛋白质水平（和mRNA水平），而对其他STATs无此作用。它还是一种DNA合成抑制剂。Fludarabine可诱导凋亡。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1032.75	现货
10mg	RMB 810.59	现货
50mg	RMB 2525.07	现货
200mg	RMB 7289.1	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达全国免运费分装免费

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的Fludarabine (NSC 118218)发表文献126篇：

Signal Transduct Target Ther, 2022, 7(1):80

PubMed: 35301282 ( click the link to review the publication )

Cell Metab, 2021, 33(1):110-127.e5

PubMed: 33171124 ( click the link to review the publication )

Cell, 2020, 182(3):685-712.e19

PubMed: 32645325 ( click the link to review the publication )

Cell Metab, 2020, 31(3):564-579

PubMed: 32130883 ( click the link to review the publication )

Nat Chem Biol, 2018, 14(10):943-954

PubMed: 30150681 ( click the link to review the publication )

Cancer Cell, 2018, 34(5):757-774

PubMed: 30423296 ( click the link to review the publication )

Cancers (Basel), 2022, 14(6)1489

PubMed: 35326640 ( click the link to review the publication )

Oncotarget, 2022, 13:319-330

PubMed: 35154579 ( click the link to review the publication )

Int J Biol Sci, 2022, 18(1):331-348

PubMed: 34975336 ( click the link to review the publication )

Hum Cell, 2022, 10.1007/s13577-022-00671-y

PubMed: 35118583 ( click the link to review the publication )

Transl Cancer Res, 2022, 11(1):206-216

PubMed: 35261897 ( click the link to review the publication )

Cell Rep, 2021, 34(1):108584

PubMed: 33406422 ( click the link to review the publication )

JCI Insight, 2021, e146362

PubMed: 34784299 ( click the link to review the publication )

Signal Transduct Target Ther, 2021, 6(1):322

PubMed: 34462423 ( click the link to review the publication )

Aging (Albany NY), 2021, 13(8):12160-12178

PubMed: 33901014 ( click the link to review the publication )

Int J Mol Sci, 2021, 22(16)8864

PubMed: 34445570 ( click the link to review the publication )

Lab Invest, 2021, 10.1038/s41374-021-00703-5

PubMed: 34789838 ( click the link to review the publication )

Lab Invest, 2021, 10.1038/s41374-021-00618-1

PubMed: 34108631 ( click the link to review the publication )

Ann Transl Med, 2021, 9(5):365

PubMed: 33842586 ( click the link to review the publication )

Life Sci, 2021, S0024-3205(21)00637-8

PubMed: 34048810 ( click the link to review the publication )

Int J Med Sci, 2021, 18(15):3437-3451

PubMed: 34522170 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00639-4

PubMed: 34731453 ( click the link to review the publication )

Hum Cell, 2021, 34(6):1911-1918

PubMed: 34383271 ( click the link to review the publication )

Hum Cell, 2021, 10.1007/s13577-021-00579-z

PubMed: 34304386 ( click the link to review the publication )
Clinics (Sao Paulo), 2021, 76:e2348

PubMed: 33681944 ( click the link to review the publication )

Liver Int, 2021, 10.1111/liv.14816

PubMed: 33555112 ( click the link to review the publication )

Blood Adv, 2021, 5(14):2863-2878

PubMed: 34297045 ( click the link to review the publication )

iScience, 2021, 24(11):103339

PubMed: 34816101 ( click the link to review the publication )

Blood Adv, 2021, 5(17):3497-3510

PubMed: 34432864 ( click the link to review the publication )

Cell Res, 2020, 1-10

PubMed: 33159154 ( click the link to review the publication )

Sci Adv, 2020, 29;6(18):eaax7881

PubMed: 32494661 ( click the link to review the publication )

Cell Rep, 2020, 31(13):107825

PubMed: 32610126 ( click the link to review the publication )

Haematologica, 2020, 16 pii: haematol

PubMed: 32299906 ( click the link to review the publication )

J Exp Clin Cancer Res, 2020, 39(1):228

PubMed: 33115525 ( click the link to review the publication )

Br J Cancer, 2020, 18

PubMed: 32418995 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 5(1):34

PubMed: 32296043 ( click the link to review the publication )

Signal Transduct Target Ther, 2020, 10;5:34

PubMed: 32284883 ( click the link to review the publication )

Cell Chem Biol, 2020, 27(1):122-133

PubMed: 31836351 ( click the link to review the publication )

Front Immunol, 2020, 14;11:867

PubMed: 32477351 ( click the link to review the publication )

Cell Commun Signal, 2020, 18(1):30

PubMed: 32093731 ( click the link to review the publication )

Exp Neurol, 2020, S0014-4886(20)30337-X

PubMed: 33065077 ( click the link to review the publication )

Cancer Cell Int, 2020, 19;20:58

PubMed: 32099531 ( click the link to review the publication )

Life Sci, 2020, 265:118832

PubMed: 33259866 ( click the link to review the publication )

Cardiovasc Diagn Ther, 2020, 10(4):738-751

PubMed: 32968630 ( click the link to review the publication )

Scand J Immunol, 2020, e12981

PubMed: 33031600 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00425-8

PubMed: 32886306 ( click the link to review the publication )

Hum Cell, 2020, 10.1007/s13577-020-00420-z

PubMed: 32870449 ( click the link to review the publication )

Clin Exp Pharmacol Physiol, 2020, 4

PubMed: 32248559 ( click the link to review the publication )
Exp Lung Res, 2020, 1-9

PubMed: 33238771 ( click the link to review the publication )

J Cancer Res Clin Oncol, 2020, 146(2):329-342

PubMed: 31912229 ( click the link to review the publication )

PLoS One, 2020, 15(7):e0228302

PubMed: 32628668 ( click the link to review the publication )

Int J Cancer, 2020, 10.1002/ijc.33202

PubMed: 32638373 ( click the link to review the publication )

Front Immunol, 2020, 11:1303

PubMed: 32655571 ( click the link to review the publication )

Microb Pathog, 2020, 142:104112

PubMed: 32126255 ( click the link to review the publication )

Int J Biol Macromol, 2020, 147:616-628

PubMed: 31931060 ( click the link to review the publication )

Cell Mol Immunol, 2020, 10.1038/s41423-019-0345-7

PubMed: 31900460 ( click the link to review the publication )

Cancer Immunol Res, 2020, 8(3):292-308

PubMed: 32024640 ( click the link to review the publication )

J Microbiol Immunol Infect, 2020, 25 pii: S1684-1182(20)30001-3

PubMed: 32033858 ( click the link to review the publication )

Stem Cell Res Ther, 2020, 11(1):112

PubMed: 32169104 ( click the link to review the publication )

Blood, 2019, 134(21):1821-1831

PubMed: 31527074 ( click the link to review the publication )

Nat Chem Biol, 2019, 15(3):232-240

PubMed: 30692684 ( click the link to review the publication )

Nat Commun, 2019, 10(1):2189

PubMed: 31097698 ( click the link to review the publication )

Mucosal Immunol, 2019, 10.1038/s41385-019-0178-9

PubMed: 31182817 ( click the link to review the publication )

Redox Biol, 2019, 24:101189

PubMed: 30986607 ( click the link to review the publication )

Cancer Lett, 2019, 10.1016/j.canlet.2019.07.016

PubMed: 31352079 ( click the link to review the publication )

PLoS Pathog, 2019, 15(11):e1008037

PubMed: 31725811 ( click the link to review the publication )

Mol Ther Oncolytics, 2019,

PubMed: 30775418 ( click the link to review the publication )

Front Immunol, 2019, 10:1622

PubMed: 31379827 ( click the link to review the publication )

Am J Cancer Res, 2019, 9(12):2618-2633

PubMed: 31911850 ( click the link to review the publication )

J Immunol, 2019, 202(11):3173-3186

PubMed: 30996000 ( click the link to review the publication )

Int J Biol Macromol, 2019, 136:980-993

PubMed: 31220493 ( click the link to review the publication )

Respir Res, 2019, 20(1):184

PubMed: 31416461 ( click the link to review the publication )
Life Sci, 2019, 10.1016/j.lfs.2019.116583

PubMed: 31226417 ( click the link to review the publication )

Gut Pathog, 2019, 11:23

PubMed: 31123503 ( click the link to review the publication )

Immunobiology, 2019, 224(3):388-396

PubMed: 30846331 ( click the link to review the publication )

Appl Health Econ Health Policy, 2019, 17(6):827-839

PubMed: 31392669 ( click the link to review the publication )

J Microbiol Immunol Infect, 2019, S1684-1182(18)30306-2

PubMed: 31296484 ( click the link to review the publication )

Cancer Immunol Res, 2019, 7(12):1944-1957

PubMed: 31554639 ( click the link to review the publication )

Hepatology, 2018, 10.1002/hep.30317

PubMed: ( click the link to review the publication )

J Cell Biol, 2018, 217(4):1503-1519

PubMed: 29507126 ( click the link to review the publication )

Mol Syst Biol, 2018, 14(3):e7858

PubMed: 29507054 ( click the link to review the publication )

Oncogene, 2018, 37(17):2270-2284

PubMed: 29391602 ( click the link to review the publication )

Cell Death Dis, 2018, 9(5):459

PubMed: 29686406 ( click the link to review the publication )

Br J Cancer, 2018, 118(4):509-521

PubMed: 29348488 ( click the link to review the publication )

Expert Opin Ther Targets, 2018, 22(6):547-557

PubMed: 29702007 ( click the link to review the publication )

J Virol, 2018, 92(22)e00728-18

PubMed: 30185587 ( click the link to review the publication )

J Biol Chem, 2018, 293(16):5975-5986

PubMed: 29496996 ( click the link to review the publication )

J Inorg Biochem, 2018, 186:235-245

PubMed: 29990747 ( click the link to review the publication )

Hum Immunol, 2018, 79(12):869-875

PubMed: 30316971 ( click the link to review the publication )

Oncotarget, 2018, 9(10):9273-9284

PubMed: 29507689 ( click the link to review the publication )

Neuron, 2017, 96(6):1290-1302

PubMed: 29268096 ( click the link to review the publication )

Nat Commun, 2017, 8:15207

PubMed: 28488695 ( click the link to review the publication )

Nat Commun, 2017, 8:15776

PubMed: 28585539 ( click the link to review the publication )

Leukemia, 2017, 31(2):340-349

PubMed: 27431016 ( click the link to review the publication )

Cancer Res, 2017, 77(15):4135-4145

PubMed: 28615225 ( click the link to review the publication )

Brain Behav Immun, 2017, 60:161-173

PubMed: 27742579 ( click the link to review the publication )
Mol Cancer Res, 2017, 15(5):585-597

PubMed: 28108623 ( click the link to review the publication )

Sci Rep, 2017,

PubMed: 29259270 ( click the link to review the publication )

Sci Rep, 2017, 7(1):14416

PubMed: 29089548 ( click the link to review the publication )

Clin Immunol, 2017, 175:56-68

PubMed: 27940139 ( click the link to review the publication )

J Cell Biochem, 2017, 118(10):3249-3259

PubMed: 28262979 ( click the link to review the publication )

Inflammation, 2017, 40(5):1726-1734

PubMed: 28656529 ( click the link to review the publication )

Mol Med Rep, 2017, 16(6):9111-9119

PubMed: 28990062 ( click the link to review the publication )

Mol Med Rep, 2017, 16(5):6405-6411

PubMed: 28901399 ( click the link to review the publication )

PLoS One, 2017, 12(6):e0180244

PubMed: 28665978 ( click the link to review the publication )

J Clin Invest, 2016, 126(1):181-94

PubMed: 26619119 ( click the link to review the publication )

J Exp Med, 2016, 19;213(10):2209-26

PubMed: 27621415 ( click the link to review the publication )

Cancer Res, 2016, 76(4):818-30

PubMed: 26837767 ( click the link to review the publication )

Am J Physiol Renal Physiol, 2016, 310(11):F1284-94

PubMed: 26984954 ( click the link to review the publication )

Int Immunopharmacol, 2016, 36:199-204

PubMed: 27160867 ( click the link to review the publication )

FEBS Lett, 2016, 590(1):53-67

PubMed: 26762170 ( click the link to review the publication )

Biogerontology, 2016, 17(5-6):907-920

PubMed: 27484416 ( click the link to review the publication )

Oncotarget, 2016, 8(31):50570-50581

PubMed: 28881584 ( click the link to review the publication )

EMBO Mol Med, 2015, 10.15252/emmm.201404580

PubMed: 25759362 ( click the link to review the publication )

Eur J Immunol, 2015, 45(10):2834-46

PubMed: 26255980 ( click the link to review the publication )

Phytother Res, 2015, 29(7):1088-96

PubMed: 25881570 ( click the link to review the publication )

Int Immunopharmacol, 2015, 28(1):61-9

PubMed: 26044347 ( click the link to review the publication )

Mol Med Rep, 2015, 12(6):7869-76

PubMed: 26497667 ( click the link to review the publication )

Oncotarget, 2015, 6(41):43992-4004

PubMed: 26556857 ( click the link to review the publication )

J Allergy Clin Immunol, 2015, 136(6):1690-1694

PubMed: 26371842 ( click the link to review the publication )
Basic Res Cardiol, 2014, 109(4):419

PubMed: 24907869 ( click the link to review the publication )

Cell Death Dis, 2014, 5:e1512

PubMed: 25375377 ( click the link to review the publication )

Mol Cancer Ther, 2014, 13(10):2276-87

PubMed: 25122069 ( click the link to review the publication )

J Biol Chem, 2014, 289(14):9952-60

PubMed: 24550394 ( click the link to review the publication )

Mol Cell Biol, 2014, 34(24):4368-78

PubMed: 25312644 ( click the link to review the publication )

Mol Cancer Ther, 2013, 12(7):1299-309

PubMed: 23657945 ( click the link to review the publication )

产品安全说明书

STAT抑制剂选择性比较

生物活性

产品描述

靶点

STAT1 ^[4]
(Vascular smooth muscle cells)

体外研究

Fludarabine有效抑制RPMI8226细胞增殖,呈时间浓度依赖性。Fludarabine处理MM.1S和MM.1R细胞48小时的IC50分别为13.48μg/mL和33.79μg/mL。而Fludarabine处理U266细胞48小时的IC 50为222.2μg/mL。Fludarabine处理可增加处于细胞周期G 1期的细胞数量，并伴随着处于细胞周期S期细胞数量的减少，对细胞周期的影响呈时间依赖性。Fludarabine在MM细胞中诱导细胞周期阻滞和细胞凋亡。Fludarabine时间依赖性的诱导caspase，-8，- 9和- 3，- 7的剪切，继而诱导PARP的剪切。氟达拉滨以时间梯度增加Bax基因表达，而Bak基因表达量不变。RPMI 8226细胞用Fludarabine处理12小时，处理后细胞膜电位降低，61.05%的细胞表达低荧光罗丹明123，而未处理的对照组细胞仅为8.62%^[1]。为提高溶解度，Fludarabine可制为一磷酸盐形式(F-ara-AMP, fudarabine)，在静脉滴注后即可即时、定量的从母核上去磷酸化。细胞内重磷酸化修饰导致Fludarabine-阿糖胞苷三磷酸（(F-ara-ATP）。该代谢产物抑制了DNA复制的几个关键过程，如DNA合成所需酶，比如核糖核酸还原酶，DNA引发酶，DNA聚合酶，具有3 ' - 5 '外切酶活性的脱氧核糖核酸聚合酶δ和ε和DNA连接酶^[2]。通过检测ICAM - 1的表达和IL - 8释放，表明Fludarabine还可以诱导前炎症刺激单核细胞的增加^[3]。Fludarabine对卵巢癌细胞系生长无影响，而它对黑色素瘤细胞系有明显的剂量依赖性抑制^[4]。Fludarabine诱导显著降低STAT - 1磷酸化，但不改变JAK 2活性。磷酸Fludarabine对三种STAT蛋白磷酸化影响不显着。Fludarabine（1.5mg）在处理2天后和7天后显著降低磷酸化STAT - 1和STAT-1总蛋白量^[5]。磷酸化JAK 2在处理后第2天变化不明显，处理后第7天的JAK表达明显受抑制。Fludarabine不影响其他STAT蛋白质，特异性抑制STAT - 1激活以降低血管平滑肌细胞体外增殖。^[5]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Formulation	Activity Description	PMID
Jeko-1	NYjSfJY2TnWwY4Tpc44hSXO\|YYm=	MmfhNlAh\|ryP	M2PBTlI1KGh?		MXHpcohq[mm2czDlfJBz\XO\|aX;uJI9nKEmGTx?=	NEPpTmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUm0NFcyOid-MkW5OFA4OTJ:L3G+
MV-4-11	NIq2Nm9CeG:ydH;zbZMhSXO\|YYm=	MVKyMlUh\|ryP	M4jJUVQ5KGh?		M3H4PIlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	NFrESog9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUGxNVU5Oyd-MkWxNVE2QDN:L3G+
THP-1	MkfCRZBweHSxc3nzJGF{e2G7	M1L1[VIvPSEQvF2=	M4Xue\|Q5KGh?		MVXpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	M4TFS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3MUGxOVg{Lz5{NUGxNVU5OzxxYU6=
MOLM 13	NUHTNlBGSXCxcITvd4l{KEG\|c3H5	NUTHU2s6Oi53IN88US=>	NEDVe4M1QCCq		MVjpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	Ml[xQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzMUG1PFMoRjJ3MUGxOVg{RC:jPh?=
KBM3/Bu2506	NG\FcXRCeG:ydH;zbZMhSXO\|YYm=	M1HzfVIvPSEQvF2=	MXK0PEBp		NHPDbnlqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=>	NUTnU5lQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWxNVE2QDNpPkK1NVEyPTh\|PD;hQi=>
Nalm-6	NHzafYlIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				NHXjUoFKSzVyPUG4JO69VQ>?	M3;B[\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xNVAyLz5{NUC2NVExOTxxYU6=
Reh	MmTCS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3LaOWlEPTB;M{Cg{txO	MnPRQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
U2937	NUG1bmhWT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				M{XPXGlEPTB;MU[g{txO	MljJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVyNkGxNFEoRjJ3ME[xNVAyRC:jPh?=
Mec-1	NGXEbIhIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				M1vtSmlEPTExvK61NFAh\|ryP	NGC2SlU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
RPMI-8226	M2f1cmdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				Mn:1TWM2OD13MECg{txO	M3PNZVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3ME[xNVAyLz5{NUC2NVExOTxxYU6=
Molt-4	M{LsVWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NIWxbFZKSzVyPUG4NEDPxE1?	NFTF[2U9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NUC2NVExOSd-MkWwOlEyODF:L3G+
Nalm-6-FluR	MnnBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MVTJR\|UxRTJ3MDFOwG0>	NXfmO45ORGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkWwOlEyODFpPkK1NFYyOTBzPD;hQi=>
Raji	NHjT[5dHfW6ldHnvckBCe3OjeR?=	M3jLW\|PDqM7:TR?=	NVzGNGhmOjRxNEivO\|IhcA>?		MX\pcoR2[2W\|IHHjZ5VufWyjdHnvcpMhd2ZicEWzMEBxPjNiYX7kJJA4O8Li	NX7RVohRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5OFA3QTVpPkK0PVQxPjl3PD;hQi=>
PBMC	NXjEV4F{TnWwY4Tpc44hSXO\|YYm=	MoXuOVAwOTByIN88US=>	NV7uOXFmOjRiaB?=	MVrEUXNQ	NI\jOFlqdmirYnn0d{BUXEGWMTDwbI9{eGixconsZZRqd25?	MoPjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O\|IoRjJ2OUGxPFczRC:jPh?=
MDA-231	MkCySpVv[3Srb36gRZN{[Xl?	M4TV[lExOCEQvF2=	M3nMbFI1KGh?	MUTEUXNQ	M3zHUIRm[3KnYYPld{BKTE9iZYjwdoV{e2mxbh?=	MlH0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O\|IoRjJ2OUGxPFczRC:jPh?=
624.38mel	MUfGeY5kfGmxbjDBd5NigQ>?	MW[1NEDPxE1?	NVqyUXZPOjRiaB?=	MXjEUXNQ	MU\k[YNz\WG\|ZYOgTWRQKGW6cILld5Nqd25?	Mon0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR7MUG4O\|IoRjJ2OUGxPFczRC:jPh?=
MDA-231	MUDGeY5kfGmxbjDBd5NigQ>?	MnL4OVAuOjByIN88US=>	M1PsUFI1KGh?	M4DOcWROW09?	MmLUbY5pcWKrdIOgTWRQKGGldHn2bZR6KGmwZHXw[Y5l\W62bImgc4YhdVKQQTDs[ZZmdHN?	NGLoblk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{NEmxNVg4Oid-MkS5NVE5PzJ:L3G+
624.38mel	NVPlW2x6TnWwY4Tpc44hSXO\|YYm=	NFzjN5k2OC1{MECg{txO	MVSyOEBp	NFG1e\|BFVVOR	NUjKdppScW6qaXLpeJMhUUSRIHHjeIl3cXS7IHnu[IVx\W6mZX70cJkhd2ZibWLORUBt\X[nbIO=	NUXxe4VbRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS5NVE5PzJpPkK0PVEyQDd{PD;hQi=>
HMECs	NYTkfWl3TnWwY4Tpc44hSXO\|YYm=	MXKxNFDDqM7:TdMg	NX;0eYRMOzcEoHi=		MWTpcohq[mm2czDJSm7Pu8LiYX7kJGxRWyCrbnT1Z4VlKFOWQWSxJJBpd3OyaH;yfYxifGmxbjDhcoQhUVKIMTDlfJBz\XO\|aX;u	MmTLQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MUGzNlcoRjJ2MkGxN\|I4RC:jPh?=
HMECs	NGLRPXRHfW6ldHnvckBCe3OjeR?=	MlLkNVAxyqEQvF5CpC=>	NFPPZo8{PsLiaB?=		MknXbY5pcWKrdIOgTWZP\|rIEoH3l[IlifGWmIIDoc5NxcG:{eXzheIlwdiCxZjDTWGFVOSCjbnSgV3RCXDNuIHL1eEBvd3Rib3[gV3RCXDJ?	MoXTQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR{MUGzNlcoRjJ2MkGxN\|I4RC:jPh?=
BJAB	M4\Ib2Fxd3C2b4Ppd{BCe3OjeR?=	MYm1xsDPxE1?	MYWyOEBp		NEm3eHJqdmS3Y3XzJINmdGxiYYDvdJRwe2m\|	M1fjRlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2MEW3NVQ4Lz5{NEC1O\|E1PzxxYU6=
I-83	NWPleohuSXCxcITvd4l{KEG\|c3H5	NUjSUm5PPcLizszN	MUGyOEBp		MnnSbY5lfWOnczDj[YxtKGGyb4D0c5Nqew>?	NYH5NXRjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOVcyPDdpPkK0NFU4OTR5PD;hQi=>
NALM6	NHT5bYFCeG:ydH;zbZMhSXO\|YYm=	NVrPS\|VtPcLizszN	Mlr3NlQhcA>?		M2e5Volv\HWlZYOgZ4VtdCCjcH;weI9{cXN?	NWfwdYc5RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkSwOVcyPDdpPkK0NFU4OTR5PD;hQi=>
DU-145	Mn7nS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?	MmGxNE0yOCEQvHevcYw>	MUC0PEBpyqB?		M3P2RolvcGmkaYTzJINmdGxiZ4Lve5RpKGmwIHGg[I9{\S2mZYDlcoRmdnRibXHucoVz	M3jVe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|N{O0PFE2Lz5{M{ezOFgyPTxxYU6=
Nalm-6	NFrIcZdHfW6ldHnvckBCe3OjeR?=	M17GeVExyqEQvF2=	NHXGbpEyNzJxNDDo		NFy1R25qdmS3Y3XzJIF2fG:yaHHnfS=>	NEXzdHo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NVIzOyd-MkO2PFEzOjN:L3G+
Reh	Mn7uSpVv[3Srb36gRZN{[Xl?	MlzONVDDqM7:TR?=	MVSxM\|IwPCCq		NVLYWXNtcW6mdXPld{BifXSxcHjh[5k>	NHnpXIY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{[4NVIzOyd-MkO2PFEzOjN:L3G+
Nalm-6	MnnQS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				NVPteYx1UUN3MDFijNwyOOLCid88US=>	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOzZ6MUKyN{c,OjN4OEGyNlM9N2F-
Reh	M4HBPWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				NXvsN5R2UUN3MDFijNwyOOLCid88US=>	NUjpRVNRRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2PFEzOjNpPkKzOlgyOjJ\|PD;hQi=>
HEC1A	M3jhcWdzd3e2aDDJcohq[mm2aX;uJGF{e2G7	NXHBc5ExOTByLUWwNEDPxE1?	NELINmYzPCCq		MlPXbY5pcWKrdIOgZ4VtdCCpcn;3eIghcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NULlNZY{RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
AN3CA	NHvv[JdIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=	NEH0WVMyODBvNUCwJO69VQ>?	NE\ab3UzPCCq		NWfBXmwycW6qaXLpeJMh[2WubDDndo94fGhiaX6gZUBld3OnLXTldIVv\GWwdDDtZY5v\XJ?	M4XFWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUm1Olk4Lz5{M{W5OVY6PzxxYU6=
HEC50B	MVTHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?	NISwbXoyODBvNUCwJO69VQ>?	NF\DdWczPCCq		NGjpSXJqdmirYnn0d{Bk\WyuIHfyc5d1cCC\|bHnnbJRtgQ>?	M3LzVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|NUm1Olk4Lz5{M{W5OVY6PzxxYU6=
HEC1A	M1iyUmFxd3C2b4Ppd{BCe3OjeR?=	M3vYN\|IxNzFyMDFOwG0>	NHT0PFMzPCCq		NWPEdWR7cW6mdXPld{BieG:ydH;zbZMhcW5iYTDkc5NmNWSncHXu[IVvfCCvYX7u[ZI>	NFXr[Hc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5OVY6Pyd-MkO1PVU3QTd:L3G+
AN3CA	MXLBdI9xfG:\|aYOgRZN{[Xl?	NITuVYIzOC9zMECg{txO	NYH3VXlWOjRiaB?=		Ml7ObY5lfWOnczDhdI9xfG:\|aYOgbY4h[SCmb4PlMYRmeGWwZHXueEBu[W6wZYK=	NXuwSmtJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO1PVU3QTdpPkKzOVk2Pjl5PD;hQi=>
HEC50B	M4XZbWFxd3C2b4Ppd{BCe3OjeR?=	MYOyNE8yODBizszN	NXnHO\|dPOjRiaB?=		MnjNbY5lfWOnczDhdI9xfG:\|aYOgd4xq\2i2bIm=	NFfjOXE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{M{W5OVY6Pyd-MkO1PVU3QTd:L3G+
EHEB	MV\BdI9xfG:\|aYOgRZN{[Xl?	Ml7SOFAh\|ryP	NHHDWnozPCCq		NEDkTIFqdmS3Y3XzJIFxd3C2b4Ppdy=>	NWnTR5hVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO0PVcxPzVpPkKzOFk4ODd3PD;hQi=>
A549	MVfHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MlHoTWM2OD1zNT63xtEzNjhiwsXN	NYLaV\|E6RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzO\|cyQTJpPkKzN\|c4OTl{PD;hQi=>
A549 GAPDH-deficient	MVXHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MmDyTWM2OD1zOD61xtEzNjNiwsXN	M4DpTVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ\|M{e3NVkzLz5{M{O3O\|E6OjxxYU6=
CLL	MoTrRZBweHSxc3nzJGF{e2G7	NVTpOppROTBizszNxsA>	MkD3NlQuQTZiaB?=		M3\kXIlv\HWlZYOgZZBweHSxdHnjJINmdGxiZHXheIg>	M13zS\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ{MkC3Olg3Lz5{MkKwO\|Y5PjxxYU6=
MEC1	NWTLSZlKSXCxcITvd4l{KEG\|c3H5	MV:xNFDDqM7:TR?=	M373eFczKGh?		NULsR25ocW6mdXPld{BieG:ydH;zbZMhe2mpbnnmbYNidnSueR?=	MkLSQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjJzM{K5O\|MoRjJ{MUOyPVc{RC:jPh?=
U937	NI[1fWdCeG:ydH;zbZMhSXO\|YYm=	NEnmVVExNjhizszN	Mn[2OE01QCCq		NULsb5pGcW6mdXPld{BieG:ydH;zbZMhe2yrZ3j0cJk>	MUi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB5NEewNEc,OjJyN{S3NFA9N2F-
U937	M1vxUWFxd3C2b4Ppd{BCe3OjeR?=	NHzJTFEyKM7:TR?=	MU[5OkBp		NGm3NWZqdmS3Y3XzJIFxd3C2b4Ppd{B{dGmpaITsfS=>	MXq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{M{WyN{c,OjJyMkO1NlM9N2F-
Daudi	NIrnT5hCeG:ydH;zbZMhSXO\|YYm=	MoLtNlAh\|ryP	M1O1UVk3KGh?		M{D2WYlv\HWlZYOgZZBweHSxc3nzJJNtcWeqdHz5	MWi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOjB{M{WyN{c,OjJyMkO1NlM9N2F-
J45.01	NFzNWmhCeG:ydH;zbZMhSXO\|YYm=	M{Hk[lEh\|ryP	MknUPVYhcA>?		MUPpcoR2[2W\|IHHwc5B1d3OrczDzcIlocHSueR?=	NVrrcXdZRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkKwNlM2OjNpPkKyNFI{PTJ\|PD;hQi=>
RPMI 8226	MnLBS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M2T3UmlEPTB;MkWuPeKhyrIEoEOuO{DPxE1?	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
CEM	NXy5TXFiT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MWPJR\|UxRTJwNNMgxtHDqDBwNDFOwG0>	NYPWZXhyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkG5OFgzPjRpPkKxPVQ5OjZ2PD;hQi=>
Raji	M1j6c2dzd3e2aDDJcohq[mm2aX;uJGF{e2G7				MkTOTWM2OD1yLkS3xsDDucLiMD6wOEDPxE1?	NGi3Uoc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MUm0PFI3PCd-MkG5OFgzPjR:L3G+
U937	MmLPS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MWrJR\|UxRTBwMkVCpOKyyqByLkC0JO69VQ>?	M2LENFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzOUS4NlY1Lz5{MUm0PFI3PDxxYU6=
K562	MWDHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M3XKSmlEPTB;MD60OOKhyrIEoECuNFUh\|ryP	MUS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTl2OEK2OEc,OjF7NEiyOlQ9N2F-
NALM-6	MULBdI9xfG:\|aYOgRZN{[Xl?	M2fTPFExKM7:TdMg	NUTnS3BPOjRiaB?=		M1Toe4lv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl?	MWC8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zOTZ7OUO4N{c,OjF4OUmzPFM9N2F-
JMV-3	Ml31RZBweHSxc3nzJGF{e2G7	M1jzXVExKM7:TdMg	NETxToYzPCCq		M1XEPYlv\HWlZYOgZ4VtdCCjcH;weI9{cXNic3zp[4h1dHl?	M4n4[lxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzNkm5N\|g{Lz5{MU[5PVM5OzxxYU6=
EHEB	MoOySpVv[3Srb36gRZN{[Xl?	NF3TSHU2NTVyIN88US=>	NFHVc20zPCCq		M{PZeIRm[3KnYYPld{BxOjFiZYjwdoV{e2mxbjDzbYdvcW[rY3HueIx6	M{DMe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMU[4N\|kyLz5{MUG2PFM6OTxxYU6=
JVM-2	NF2wOJFHfW6ldHnvckBCe3OjeR?=	M37welMxKM7:TR?=	NFLpUHIzPCCq		MkW0[IVkemWjc3XzJJAzOSCneIDy[ZN{cW:w	M{XHeVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJzMU[4N\|kyLz5{MUG2PFM6OTxxYU6=
KBM3/Bu2506	NH3yR4xIem:5dHigTY5pcWKrdHnvckBCe3OjeR?=				MXHJR\|IxRTBwNkegxtVO	NGfVcmg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{MEmzN\|UxQSd-MkC5N\|M2ODl:L3G+
KBM3/Bu2506	NXnQU4JGT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=	MX:wMlYh\|ryP	NFvhSHMzPCCq		M3XFfIlv[3KnYYPld{B1cGViY3XscEBnemGldHnvckBqdiCVLYDoZZNm	MljMQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB7M{O1NFkoRjJyOUOzOVA6RC:jPh?=
MDA-MB-231	MkOxS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M4nESWlEPTB;ND6wJO69VQ>?	Ml7wQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjB2NEezPVAoRjJyNES3N\|kxRC:jPh?=
MCF-7	MXLHdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				M4rObWlEPTB;MUWuNEDPxE1?	NV3iZnVHRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0OFc{QTBpPkKwOFQ4OzlyPD;hQi=>
HLE-B3	NYjqfVZxTnWwY4Tpc44hSXO\|YYm=	MnvUNlUh\|ryP	MXS0PEBp		NEHzZ5RjdG:la4OgTWZPNc7\|4pETbY5lfWOnZDDTWGFVOSCyaH;zdIhwenmuYYTpc44h[W6mIFnEU{BmgHC{ZYPzbY9v	NViy[WRIRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC0N\|UyPThpPkKwOFM2OTV6PD;hQi=>
K562	NXzMTpJMT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MnPpO\|IhcA>?		MVLJR\|UxRTNwMzDuUS=>	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODNyN{G5PEc,OjB\|MEexPVg9N2F-
BW-225	MX3Hdo94fGhiSX7obYJqfGmxbjDBd5NigQ>?				MYDJR\|IxRTFwM{egx7cyOOLKkklCpO69VcLi	M2L5[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
OH-65	MmTzS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MXnJR\|IxRTFwM{egx7cyOOLKkklCpO69VcLi	MWK8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDZ4MUO4NEc,OTh4NkGzPFA9N2F-
GR-145	MnPFS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MnjwTWMzOD1{Lke0JOOYKDFy4pkSPEAh\|ryPwrC=	NEP1OIU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zOE[2NVM5OCd-MUi2OlE{QDB:L3G+
A549	MkfYS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				MlnkTWMzOD13LkS4JOOYKDFy4pkSPEDPxE4EoB?=	MmX3QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkGzPFAoRjF6Nk[xN\|gxRC:jPh?=
CaSki	MkDIS5Jwf3SqIFnubIljcXSrb36gRZN{[Xl?				M3XvN2lEOjB;MT6zO{DEnyBzMPMIllch\|ryPwrC=	Mof6QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOTh4NkGzPFAoRjF6Nk[xN\|gxRC:jPh?=
ZMK-1	NYHLOI53T3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=				MnHLTWMzOD1zLkO3JOOYKDFy4pkSOkDPxE4EoB?=	M4jzNlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF6Nk[xN\|gxLz5zOE[2NVM5ODxxYU6=
SKW6.4	MlTWRZBweHSxc3nzJGF{e2G7	M4TUWlAvODFvMUCg{txO	NGHkZm4zPC92ODDo		MV;pcoR2[2W\|IHPlcIwh\GWjdHigbY4h[m:2aDD0bY1mNSCjbnSg[I9{\S1iZHXw[Y5l\W62IH3hco5meg>?	MWe8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yQDB7MkO0NEc,OThyOUKzOFA9N2F-
RPMI 8226	NWjuN5hsT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MkDoNlQhcA>?		NYPaTnE1UUN3ME2xMlU1yqEQvF2=	M3nDPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzF5OUe2NVg3Lz5zN{m3OlE5PjxxYU6=
MM.1S	NVT3V29QT3Kxd4ToJGlvcGmkaYTpc44hSXO\|YYm=		MVy0PEBp		M1vY[WlEPTB;MUOuOFjDqM7:TR?=	NGD4dJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zN{m3OlE5Pid-MUe5O\|YyQDZ:L3G+
MM.1R	M{HKfGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7		NX2xSWtlPDhiaB?=		MWHJR\|UxRTN\|Lke5JO69VQ>?	MYS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8yPzl5NkG4Okc,OTd7N{[xPFY9N2F-
U937	M{fUcGdzd3e2aDDJcohq[mm2aX;uJGF{e2G7				M3HjR2lEPTB;MzyyNFAhyrFiNU[wJI5O	NEL1ZY49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9zNUmzNFM3OSd-MUW5N\|A{PjF:L3G+
CLL5	NX71T3d5SW62aYT1cY9zKGG\|c3H5		MoTTOFghcHK\|		M{PzSWFvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JGNNVDViY3XscJMhcXOxbHH0[YQh\nKxbTDDUGwheGG2aXXueEBie3Onc4Pl[EBieyClZXzsJJZq[WKrbHn0fUBi\nSncjC0PEBpenNiYomgSmFEWyCjbnHsfZNqeyxiRVO1NEA:KDBwMU[g{txONg>?	NXr3bW9YRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
K562	Mn;oR5l1d3SxeHnjbZR6KGG\|c3H5		NWPVVGlnPzJiaILz		NFnW[5hEgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBx[WOuaYThfIVtNXKnc3nzeIFvfCCNNU[yJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSByLkK2JO69VS5?	NVn4[I1WRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkC2NFU3PTZpPkKwOlA2PjV4PD;hQi=>
CLL3	NX3FdWhbSW62aYT1cY9zKGG\|c3H5		NGi3S4Y1QCCqcoO=		MkDRRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOyClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOC5\|NTFOwG0v	NXjWcIhjRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
CLL4	NYXnXHNKSW62aYT1cY9zKGG\|c3H5		NHmwcZE1QCCqcoO=		MnzwRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNPCClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOC54NDFOwG0v	Mor1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjR4N{O3N\|koRjJ2NkezO\|M6RC:jPh?=
CEM-DNR-B	NGTVU\|ZEgXSxdH;4bYNqfHliYYPzZZk>		NXLIWWIxPzJiaILz		MlHzR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VONUSQUj3CJINmdGy\|IHHmeIVzKDd{IHjyd{BjgSCPVGSgZZN{[XluIFnDOVAhRSBzLkCxJO69VS5?	MVO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zODZyNU[1Okc,OjB4MEW2OVY9N2F-
primary CLL	MV3DfZRwfG:6aXPpeJkh[XO\|YYm=				NFjsNVREgXSxdH;4bYNqfHliYXfhbY5{fCCqdX3hckBxemmvYYL5JGNNVCClZXzsd{whVER3MDC9JFEvOSEQvF2u	MlPFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjVzNEizPVIoRjJ3MUS4N\|kzRC:jPh?=
CLL6	Mm\BRY51cXS3bX;yJIF{e2G7		NHiwWFk1QCCqcoO=		MULBcpRqfHWvb4KgZYN1cX[rdImgZYdicW6\|dDDDUGw3KGOnbHzzJIl{d2yjdHXkJIZzd21iQ1zMJJBifGmnboSgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF\BR3Mh[W6jbInzbZMtKEWFNUCgQUAyNjZizszNMi=>	NUTkPFNoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
CLL2	NXL6cIZTSW62aYT1cY9zKGG\|c3H5		MnzSOFghcHK\|		MnTORY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOiClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOi54NjFOwG0v	NULFU2FYRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkS2O\|M4OzlpPkK0Olc{PzN7PD;hQi=>
HCT116	NE\qdVdEgXSxdH;4bYNqfHliYYPzZZk>		MYC3NkBpenN?		MWPDfZRwfG:6aXPpeJkh[WejaX7zeEBpfW2jbjDIR3QyOTZiY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JHNTSiCjc4PhfUwhUUN3MDC9JFYvPiEQvF2u	MkPBQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjV2NkKyO\|coRjJ3NE[yNlc4RC:jPh?=
PBMC	NEDwZ2pEgXSxdH;4bYNqfHliYYPzZZk>		M3v0b\|Q5KGi{cx?=		NVjES4NNS3m2b4TvfIlkcXS7IHHnZYlve3RicHH0bYVvfCCSQl3DJIFnfGW{IES4JIhzeyCkeTDD[YxtXGm2cnWtRox2\SCjc4PhfUBqdiCycnXz[Y5kKG:oIH3veZNmKE1{MUDCOEBk\WyuczygTWM2OCB;IEGwJO69VS5?	M3PRSlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ3NU[yOFE4Lz5{NUW2NlQyPzxxYU6=
CHO	MYPGeY5kfGmxbjDhd5NigQ>?				M{TtOmJqdmSrbnegZYZncW6rdImg[IV1\XKvaX7l[EBjgSCmaYPwcIFk\W2nboSgc4Yhe3CnY3nmbYMh[mmwZHnu[{Bw\iCdMUK1TX1PNSh2LXHtbY5wNTNvaX;kc5Bp\W6ndHj5cEku[WSnbn;zbY5mKGmwIH3lcYJz[W6nczDv[kBEUE9iY3XscJMhe3SjYnz5JJRz[W6\|ZnXjeIVlKHerdHigeIhmKHKjdDDh[IVvd3OrbnWgRVMhemWlZYD0c5ItKEurIE2gNVAvPCEQvF2u	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek84PzB5M{KwK\|44PzB5M{KwQE9iRg>?
JVM2	MX7BcpRqfHWvb4KgZZN{[Xl?				M361T2FvfGm2dX3vdkBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFrWUVIh[2WubIOgZZN{\XO\|ZXSgZZMh[2WubDD2bYFjcWyrdImgZYZ1\XJiNEigbJJ{KGK7IF\BR3Mh[W6jbInzbZMtKEWFNUCgQUAyOC52IN88UU4>	MXu8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
HeLa	M4\sOWFvfGm2dX3vdkBie3OjeR?=				NFvwcZZCdnSrdIXtc5Ih[WO2aY\peJkh[WejaX7zeEBpfW2jbjDI[WxiKGOnbHzzJIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIJ6KE2WVDDhd5NigSxiRVO1NEA:KDF4IN88UU4>	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPDZ5M{ezPUc,OjR4N{O3N\|k9N2F-
CLL1	M2qwVmFvfGm2dX3vdkBie3OjeR?=		NH73bnA1QCCqcoO=		MljtRY51cXS3bX;yJIFkfGm4aYT5JIFo[Wmwc4SgR2xNOSClZXzsd{Bqe2:uYYTl[EBnem:vIFPMUEBx[XSrZX70JIF{e2W\|c3XkJIF{KGOnbHygeoli[mmuaYT5JIFnfGW{IES4JIhzeyCkeTDGRWNUKGGwYXz5d4l{NCCHQ{WwJF0hOTdwMTFOwG0v	M2rHe\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ2NkezO\|M6Lz5{NE[3N\|c{QTxxYU6=
CEM	NFfPe3dEgXSxdH;4bYNqfHliYYPzZZk>		NHP0XHk4OiCqcoO=		MlfkR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gR2VOKGOnbHzzJIFnfGW{IEeyJIhzeyCkeTDNWHQh[XO\|YYmsJGlEPTBiPTCxPU41QSEQvF2u	M3vme\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC1OlU3Lz5{ME[wOVY2PjxxYU6=
T47D	MX\DfZRwfG:6aXPpeJkh[XO\|YYm=		MYi3NkBpenN?		MkfTR5l1d3SxeHnjbZR6KGGpYXnud5QhcHWvYX6gWFQ4TCClZXzsd{Bi\nSncjC3NkBpenNiYomgV3JDKGG\|c3H5MEBKSzVyIE2gOFYvOiEQvF2u	NXv5XZdoRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkW0OlIzPzdpPkK1OFYzOjd5PD;hQi=>
A549	NF3H[\|dEgXSxdH;4bYNqfHliYYPzZZk>		NH7iNpQ4OiCqcoO=		M3LRd2N6fG:2b4jpZ4l1gSCjZ3HpcpN1KGi3bXHuJGE2PDliY3XscJMh[W[2ZYKgO\|IhcHK\|IHL5JG1VXCCjc4PhfUwhUUN3MDC9JFQ4NjR2IN88UU4>	M1\rXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJyNkC1OlU3Lz5{ME[wOVY2PjxxYU6=
CCRF-CEM	M2e5d2Z2dmO2aX;uJIF{e2G7	MYqxNEB2VQ>?	MmPJNUB1dyB4MDDtbY5{		MWHEdpVoKHS{YX7zdI9zfCCrbjDoeY1idiCFQ2LGMWNGVSClZXzsd{Bie3Onc4Pl[EBieyCHTmSxMY1m\GmjdHXkJJVxfGGtZTDheEAyOCC3TTDh[pRmeiBzIITvJFYxKG2rboOgZpkhdGmzdXnkJJNkcW62aXzsZZRqd25iY3;1cpRqdmdiYX7hcJl{cXN?	NUn1RnBSRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkOzPFg4ODVpPkKzN\|g5PzB3PD;hQi=>
TC32	NHvkUnByUFSVIHHzd4F6				M2rDWJFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCWQ{OyJINmdGy\|	MUm8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
U-2 OS	NEnPNHpyUFSVIHHzd4F6				NWLZOZpyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGWtNkBQWyClZXzsdy=>	NFK1UYc9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	MmTpdWhVWyCjc4PhfS=>				MULxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhSTZ5MzDj[Yxtew>?	MmXDQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
DAOY	NIf1b3RyUFSVIHHzd4F6				Mln3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKESDT2mgZ4VtdHN?	NFjmfYs9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	NF\5cYZyUFSVIHHzd4F6				NVK2SWhneUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPhc5MuOiClZXzsdy=>	MkDFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	NFjKVWlyUFSVIHHzd4F6				Mlq5dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEKWLUO3JINmdGy\|	M3vEW\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
RD	MXnxTHRUKGG\|c3H5				MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWkRiY3XscJM>	MnXjQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	NY\qe5NYeUiWUzDhd5NigQ>?				NHT3bW5yUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1utUk1UUCClZXzsdy=>	NIjtWoo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MWDxTHRUKGG\|c3H5				M162d5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCPRzC2N{ApPi2WRzDSLUBk\Wyucx?=	NUnRRZhmRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	MVnxTHRUKGG\|c3H5				M1vCNpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCEVD2xNkBk\Wyucx?=	M1HHdVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
NB1643	MUfxTHRUKGG\|c3H5				M{XvTpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCQQkG2OFMh[2WubIO=	MV68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	MnnpdWhVWyCjc4PhfS=>				MoHPdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE:KUz21NEBk\Wyucx?=	NUCycHpQRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
BT-12	NIm0emtyUFSVIHHzd4F6				MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDCWE0yOiClZXzsdy=>	NFzBcXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	MnWwdWhVWyCjc4PhfS=>				NVTzR3BSeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhVEGQLUWgZ4VtdHN?	Mk\sQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	MX\xTHRUKGG\|c3H5				MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDORk1GSmNzIHPlcIx{	MlXZQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	M1nPUZFJXFNiYYPzZZk>				MXPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	MkXVQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh41	NHjXVY1yUFSVIHHzd4F6				MmjFdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFKqNEGgZ4VtdHN?	Mnu4QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
A673	NEjYT2NyUFSVIHHzd4F6				MWjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDBOlc{KGOnbHzzLS=>	M1LOcVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NET4VWFyUFSVIHHzd4F6				M{HldZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJGJVNTN5IHPlcIx{	M1jYWlxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
MG 63 (6-TG R)	MV7xTHRUKGG\|c3H5				NHjNRXpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	NFP4XmY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh30	NVXYPWNNeUiWUzDhd5NigQ>?				M37oUZFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHJpOzBiY3XscJM>	NHfVb4w9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
U-2 OS	M3;OTJFJXFNiYYPzZZk>				MnS2dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgWU0zKE:VIHPlcIx{	M1qxfVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
OHS-50	NGXZNW9yUFSVIHHzd4F6				MVvxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDPTHMuPTBiY3XscJM>	MofKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SK-N-SH	MUnxTHRUKGG\|c3H5				NH23T4lyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	MXS8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	MorRdWhVWyCjc4PhfS=>				NUXzdHA2eUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhWkRiY3XscJM>	MYO8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
Daoy	MkDOdWhVWyCjc4PhfS=>				NYjwW2preUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCGYX;5JINmdGy\|	NIPocVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	NUDmN4lzeUiWUzDhd5NigQ>?				MVfxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBQenSqb3fvcoFtKDOGIHPhd5Bie2Vic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	NYHUR49iRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
TC32	M3e0dJFJXFNiYYPzZZk>				MlPHdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBVSzN{IHPlcIx{	NHfHVHk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
MG 63 (6-TG R)	MV;xTHRUKGG\|c3H5				MoKwdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohV3K2aH;nc45idCB\|RDD2bYFjcWyrdImgd4Nz\WWwIH\vdkBOTyB4MzCoOk1VTyCUKTDj[Yxtew>?	M4L6O\|xiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NIDsPJZyUFSVIHHzd4F6				NGD4fGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiU1qtS2JOOiClZXzsdy=>	NEjzXZg9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	NVjISG1yeUiWUzDhd5NigQ>?				NYTu[WlEeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IGPLMW4uVUNiY3XscJM>	Mnj1QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB-EBc1	MnPqdWhVWyCjc4PhfS=>				NFLncmVyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKtSWJkOSClZXzsdy=>	MoH5QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
LAN-5	NXrTOoY5eUiWUzDhd5NigQ>?				MnnLdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NF;vXI89[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	MkTzdWhVWyCjc4PhfS=>				MXLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhWmhzODDj[Yxtew>?	NWfpTZRVRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
NB1643	NYXUcWpYeUiWUzDhd5NigQ>?				MmTidWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	NInESJk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-MC	MWHxTHRUKGG\|c3H5				NHHCeXlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBUUy2QLV3DJINmdGy\|	NGLiSHQ9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SJ-GBM2	MnrGdWhVWyCjc4PhfS=>				NX\R[HFyeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MlPlQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
TC32	MXPxTHRUKGG\|c3H5				MYPxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDUR\|MzKGOnbHzz	MnXFQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
Rh18	MUDxTHRUKGG\|c3H5				NHrkSldyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCFb37mbZJu[XSxcomgd4Nz\WWwIH\vdkBTcDF6IHPlcIx{	NFnib449[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Saos-2	MYnxTHRUKGG\|c3H5				MlHvdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV4Fwey1{IHPlcIx{	MlT2QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
SJ-GBM2	Mk\TdWhVWyCjc4PhfS=>				NXn5PGJXeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiT4L0bI9od26jbDCzSEB3cWGkaXzpeJkhe2O{ZXXuJIZweiCVSj3HRm0zKGOnbHzz	MXi8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
RD	NWGybGpueUiWUzDhd5NigQ>?				NEPoeHpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCRcoToc4dwdmGuIEPEJJZq[WKrbHn0fUB{[3KnZX6g[o9zKFKGIHPlcIx{	MoT0QIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	procaspase-9 / procaspase-3; PubMed: 27223263 Oncotarget Procaspase-9 and procaspase-3 were analyzed by Western blot in CLL cells from three patients after a 48 h-incubation in the absence or presence of 3 μM aphidicolin (APC) with or without fludarabine at 0.3 and 1 μM. β-Actin served as a loading control. p-p53 / p53; PubMed: 27223263 Oncotarget (A–B) CLL cells from 3 different patients were incubated for 24 h with fludarabine at the indicated concentrations in the absence or presence of 3 μM aphidicolin (APC). Phosphorylation of p53 at Ser-15 and total p53 were analyzed by Western blot. Data sho䲧疝Ỵ疞㧀疜膉痘瘿�෋ᾰƌ෋à㺣痖帉痖Ѐ瑖堘𢡄빢᎒෋à鑸᎒彿堙奋堙巫堙᎒ﻺ᎒彿堙ﻮ᎒ STAT1; PubMed: 26677135 Int J Mol Med Representative western blot analysis of STAT1 in RAW 264.7 cells treated with STAT1 inhibitor fludarabine (Flu) for 24 h.	27223263 26677135
Immunofluorescence	α-SMA / Vimentin; PubMed: 28322315 Sci Rep FLU (50 μM) reduces the expression of α-SMA and Vimentin protein in primary mouse activated HSCs (Hepatic Stellate Cells).	28322315
Growth inhibition assay	Cell viability ; PubMed: 24956101 PLoS One CLL cells RPMI/0.1% FBS were cultured on 0.5% BSA or 150 nM MMP-9 for 1 h prior to adding the indicated concentrations of fludarabine (Fluda). After 48 h (Fluda) cell viability was determined by flow cytometry using FITC-Annexin V and PI.	24956101

体内研究

PBS对照组中肿瘤细胞增长迅速，25天内扩增为10倍。而用40mg/kgFludarabine处理的肿瘤扩增不超过5倍。40mg/kgFludarabine对RPMI 8226细胞有明显的抗肿瘤效果。RPMI 8226处理肿瘤细胞十天后增加凋亡细胞核数量。^[1] Fludarabine可在免疫缺陷小鼠中有效抑制RPMI 8226细胞的骨髓转移。

细胞实验： ^[1]	- 合并 Cell lines: 地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系 Concentrations: 2 μg/Ml Incubation Time: 24 小时 Method: 对地塞米松敏感(MM.1S) 和耐受 (MM.1R) 的人MM 细胞系, RPMI8226和 U266 细胞系以5 × 10⁵细胞密度铺板，实验组均包括氟达拉滨处理和空白对照组。处理后细胞用PBS清洗两次然后用70%冰乙醇固定，离心后用含100μg/mL核糖核酸酶PBS重悬浮，37ºC孵育30分钟。样品重悬于25μg/mL碘化吡啶中，用流式细胞仪检测。根据产品说明用Annexin V-FITC试剂盒检测细胞凋亡。利用TUNEL（末端脱氧核苷酸转移酶介导脱氧核苷酸缺口末端标记）法和原位细胞凋亡检测试剂盒处理细胞，最后用流式细胞仪分析。 (Only for Reference)
动物实验： ^[1]	- 合并 Animal Models: 携带RPMI 8226肿瘤细胞的免疫缺陷型小鼠 Dosages: 40 mg/kg Administration: 腹腔注射 (Only for Reference)

参考文献

- 合并

溶解度 (25°C)

体外	DMSO	57 mg/mL (199.83 mM)
	Water	Insoluble
	Ethanol	Insoluble
体内	从左到右依次将纯溶剂加入产品，现配现用(数据来自Selleck实验检测而非文献)： 5%DMSO+40%PEG300+5%Tween80+50%ddH2O	8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download Fludarabine (NSC 118218) SDF

分子量	285.23
化学式	C₁₀H₁₂FN₅O₄
CAS号	21679-14-1
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	FaraA, Fludarabinum

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

每只动物给药体积

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、SDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

NCT Number	Recruitment	interventions	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT03832127	Not yet recruiting	Drug: 18F-Fludarabine	Myeloma	Nantes University Hospital\|Cyceron	April 1 2022	Phase 1
NCT04526795	Recruiting	Drug: Cytarabine\|Drug: Fludarabine\|Drug: Pegcrisantaspase	Blast Phase Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent Acute Biphenotypic Leukemia\|Recurrent Acute Lymphoblastic Leukemia\|Recurrent Acute Myeloid Leukemia\|Recurrent Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Recurrent T-Cell Prolymphocytic Leukemia\|Refractory Acute Biphenotypic Leukemia\|Refractory Acute Lymphoblastic Leukemia\|Refractory Acute Myeloid Leukemia\|Refractory Chronic Myelogenous Leukemia BCR-ABL1 Positive\|Refractory T-Cell Prolymphocytic Leukemia	M.D. Anderson Cancer Center\|National Cancer Institute (NCI)	April 9 2021	Phase 1

技术支持

在订购、运输、储存和使用我们的产品的任何阶段，您遇到的任何问题，均可以通过拨打我们的热线电话400-668-6834，或者技术支持邮箱tech@selleck.cn，直接联系到我们。我们会在24小时内尽快联系您。

操作手册

如果有其他问题，请给我们留言。

常见问题及建议解决方法

问题 1：
how to re-suspend and deliver the inhibitor for in vivo experiments?
回答：
For S1491, Fludarabine, we tested a vehicle: 30% Propylene glycol, 5% Tween 80, 65% D5W that you can resuspend the compound in at up to 30mg/ml. It's a suspension and can only be given via oral gavage.

研究领域

产品类型

定制您的化合物库

Fludarabine (NSC 118218)

客户使用Selleck生产的Fludarabine (NSC 118218)发表文献126篇：

产品安全说明书

STAT抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download Fludarabine (NSC 118218) SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

临床试验信息 (data from https://clinicaltrials.gov, updated on 2022-01-17)

技术支持

常见问题及建议解决方法

STAT Signaling Pathway Map

相关STAT产品